173 related articles for article (PubMed ID: 7736717)
1. British Blood Transfusion Society. Blood Component Special Interest Group Symposium. Towards 'purer and safer' blood components and blood products. London, United Kingdom, 5 May 1994. Abstracts.
Clin Lab Haematol; 1994 Dec; 16(4):379-406. PubMed ID: 7736717
[No Abstract] [Full Text] [Related]
2. [Safety of blood and blood products in the face of recent reports on the transmissibility of Alzheimer's disease in an animal experiment].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Apr; 56(4):584. PubMed ID: 23529604
[No Abstract] [Full Text] [Related]
3. Present status of blood component labeling. Specific proposals that meet current needs and provide for the future. International Society of Blood Transfusion Working Party on Automation and Data Processing.
Steane EA
Vox Sang; 1994; 67 Suppl 3():117-9. PubMed ID: 7975472
[No Abstract] [Full Text] [Related]
4. [Safety of blood and blood products in the face of recent reports on the transmissibility of Alzheimer's disease in an animal experiment. Explanation to comment].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Apr; 56(4):585-9. PubMed ID: 23529605
[No Abstract] [Full Text] [Related]
5. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
Dumont LJ
Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
[No Abstract] [Full Text] [Related]
6. Logistical problems of supplying leucodepleted blood components within the national blood service.
Tandy N
Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160
[No Abstract] [Full Text] [Related]
7. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force.
Voak D; Cann R; Finney RD; Fraser ID; Mitchell R; Murphy MF; Napier JA; Phillips P; Rejman AJ; Waters AH
Transfus Med; 1994 Mar; 4(1):63-9. PubMed ID: 8012495
[No Abstract] [Full Text] [Related]
8. [Audit of labile blood product supplies].
Cabaud JJ
Transfus Clin Biol; 2000 Jun; 7 Suppl 1():75s-79s. PubMed ID: 10919230
[TBL] [Abstract][Full Text] [Related]
9. Quality assurance of blood components prepared in the blood transfusion center/blood bank.
Vox Sang; 1994; 67(1):99-111. PubMed ID: 7975467
[No Abstract] [Full Text] [Related]
10. [Transfusion of homologous red cells: products, indications and alternatives].
Therapie; 2004; 59(3):349-73. PubMed ID: 15559188
[No Abstract] [Full Text] [Related]
11. [Can virus safety of blood products be assured?].
Krusius T
Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
[No Abstract] [Full Text] [Related]
12. [Quality assurance management system for therapy with blood and blood products].
Diekamp U
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Oct; 33(10):664-5. PubMed ID: 9825053
[No Abstract] [Full Text] [Related]
13. The administration of blood components: a British Society for Haematology Guideline.
Robinson S; Harris A; Atkinson S; Atterbury C; Bolton-Maggs P; Elliott C; Hawkins T; Hazra E; Howell C; New H; Shackleton T; Shreeve K; Taylor C
Transfus Med; 2018 Feb; 28(1):3-21. PubMed ID: 29110357
[No Abstract] [Full Text] [Related]
14. Report about the haemovigilance postgraduate course of the interdisciplinary European society for haemapheresis and haemotherapy.
Moog R
Transfus Apher Sci; 2007 Oct; 37(2):177-8. PubMed ID: 17977795
[No Abstract] [Full Text] [Related]
15. Pathogen Reduction: The State of the Science in 2019.
Gehrie EA; Rutter SJ; Snyder EL
Hematol Oncol Clin North Am; 2019 Oct; 33(5):749-766. PubMed ID: 31466602
[TBL] [Abstract][Full Text] [Related]
16. [Transfusions of blood and blood products and virus infections].
Wróblewska M; Piotrowska E; ĺuczak M
Postepy Hig Med Dosw; 2002; 56(2):221-40. PubMed ID: 12107964
[TBL] [Abstract][Full Text] [Related]
17. Blood components: current challenges.
Rouger P
Transfus Clin Biol; 2007 Dec; 14(6):496-8. PubMed ID: 18420438
[TBL] [Abstract][Full Text] [Related]
18. [Scandinavian recommendations for transfusion medicine].
Eklund J; Jørgensen J; Högman C; Jensson O; Kornstad L
Nord Med; 1991; 106(11):299-300. PubMed ID: 1945807
[TBL] [Abstract][Full Text] [Related]
19. [Eliminating alanine aminotransferase (ALT) determination in screening of blood components for transfusion and plasma for fractionation. At the 52nd Meeting of the Blood Professional Circle 1 October 2003 the following vote (V30) was delivered].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):82. PubMed ID: 15205830
[No Abstract] [Full Text] [Related]
20. [Guidelines of the German Medical Association for Therapy with Blood Components and Plasma Derivatives--an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy].
Heim MU
Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Mar; 44(3):186-97; quiz 199. PubMed ID: 19266420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
